Effectiveness of COVID-19 vaccines in preventing hospitalizations among immunocompromised adults

In a recent MMWR published on the United States Center for Disease Control and Prevention (US-CDC) website, researchers investigated the efficacy of monovalent messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccines in immunocompromised adults during the Omicron dominance period starting December 2021.

Sudy: Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022. Image Credit: M-Foto/Shutterstock
Sudy: Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022. Image Credit: M-Foto/Shutterstock

Further, they investigated whether these individuals might benefit from novel bivalent mRNA COVID-19 vaccine boosters that directly target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant.

Background

The Advisory Committee on Immunization Practices (ACIP), on August 13, 2021, recommended an expanded primary series of three doses of an mRNA COVID-19 vaccine for immunocompromised adults in the US. With the launch of a new bivalent mRNA COVID-19 vaccine booster, the ACIP updated its recommendations. These novel vaccines contain components of the BA.4 and BA.5 sublineages of Omicron B.1.1.529. It raised the need to evaluate the efficacy of monovalent COVID-19 vaccines in immunocompromised people.

About the study

In the present study, researchers estimated vaccine effectiveness (VE) for monovalent two-, three-, and four-dose mRNA vaccines in preventing COVID-19–related hospitalization in immunocompromised adults. They estimated VE of two- and three-doses for the Omicron period (all sublineages combined) and for each sublineage predominance period. The VE estimates for four doses were restricted to the combined period, including BA.2/BA.2.12.1 and BA.4/BA.5 predominance periods, because of its limited coverage among individuals eligible for vaccination before mid-March 2022.

The team examined patients with five exclusive immunocompromising conditions (e.g., organ transplant recipients and solid malignancy). They also covered individuals with more than one immunodeficiency in their analyses. The current multistate VISION Network study used a test-negative design to compare the odds of prior vaccination in the case and control persons with positive or negative reverse transcription-polymerase chain reaction (RT-PCR) results, respectively.

Study findings

Between December 16, 2021, and August 20, 2022, 34,220 immunocompromised adults with a median age of 69 years needed hospitalization for COVID-19–like illness. Of these, 8,798, 14,286, and 2,393 patients had received two-, three-, and four-doses of mRNA COVID-19 vaccines, respectively, including 11,088 patients who received their third vaccine dose ≥90 days before the study index date. These 11,088 patients were, thus, eligible for the fourth dose of a monovalent mRNA COVID-19 vaccine.

During the combined dominance periods of Omicron sublineages, more immunocompromised people became eligible for the fourth vaccine dose. Consequently, VE for monovalent mRNA vaccine ≥90 days after the third dose rose to 32%.

Following the primary vaccination series, VE during the combined Omicron period was 36% at ≥14 days. VE estimates showed an increase to 69% and 44%, seven to 89 days after the third dose and ≥90 days after the third dose. Further stratification by Omicton sublineages showed that during the BA.1 dominance period, VE was nearly 67% ≥7 days after receipt of the third dose than during the BA.2/BA.2.12.1 and BA.4/BA.5 periods, when VE was only 32% and 35%, respectively.

Furthermore, VE varied by the immunocompromising condition at ≥7 days after receiving the third vaccine dose. While VE was 43% for organ or stem cell transplant recipients, it rose to 70% for those with a solid malignancy.

Conclusions

Studies have shown that immunocompromised individuals have been disproportionately affected by the COVID-19 pandemic. Despite additional dosing recommendations, the VE of mRNA vaccines decreased during the Omicron period compared with that during pre-Omicron periods in these individuals. Even a three-dose monovalent vaccination series offered moderate protection against hospitalization in immunocompromised people.

People with specific immunocompromising conditions had even lower VE (e.g., solid organ or stem cell transplant recipients). Thus, these people might benefit from updated bivalent vaccine booster doses, as per AICP recommendations. Notably, these vaccines target recently circulating Omicron sublineages.

Furthermore, immunocompromised people should be prioritized for additional COVID-19 protective measures. For instance, prophylactic antibody therapy, early access to antivirals, and even nonpharmaceutical interventions, such as masks or respirators. Lastly, the researchers emphasized the need for further studies of VE of updated mRNA COVID-19 vaccines in immunocompromised people.

Journal reference:
Neha Mathur

Written by

Neha Mathur

Neha is a digital marketing professional based in Gurugram, India. She has a Master’s degree from the University of Rajasthan with a specialization in Biotechnology in 2008. She has experience in pre-clinical research as part of her research project in The Department of Toxicology at the prestigious Central Drug Research Institute (CDRI), Lucknow, India. She also holds a certification in C++ programming.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mathur, Neha. (2022, October 24). Effectiveness of COVID-19 vaccines in preventing hospitalizations among immunocompromised adults. News-Medical. Retrieved on February 01, 2023 from https://www.news-medical.net/news/20221024/Effectiveness-of-COVID-19-vaccines-in-preventing-hospitalizations-among-immunocompromised-adults.aspx.

  • MLA

    Mathur, Neha. "Effectiveness of COVID-19 vaccines in preventing hospitalizations among immunocompromised adults". News-Medical. 01 February 2023. <https://www.news-medical.net/news/20221024/Effectiveness-of-COVID-19-vaccines-in-preventing-hospitalizations-among-immunocompromised-adults.aspx>.

  • Chicago

    Mathur, Neha. "Effectiveness of COVID-19 vaccines in preventing hospitalizations among immunocompromised adults". News-Medical. https://www.news-medical.net/news/20221024/Effectiveness-of-COVID-19-vaccines-in-preventing-hospitalizations-among-immunocompromised-adults.aspx. (accessed February 01, 2023).

  • Harvard

    Mathur, Neha. 2022. Effectiveness of COVID-19 vaccines in preventing hospitalizations among immunocompromised adults. News-Medical, viewed 01 February 2023, https://www.news-medical.net/news/20221024/Effectiveness-of-COVID-19-vaccines-in-preventing-hospitalizations-among-immunocompromised-adults.aspx.

Comments

  1. Nicolas Coveria Nicolas Coveria United States says:

    Unfortunately the CDC is now infamous for their 'guess work' on covid matters and hardly anyone - even those w/o a scientific background take their messaging seriously anymore. I must say, they definitely earned their new found fame as promoters of guess work!!
    Maybe if they actually start doing their jobs and not taking the word of big pharma on clinical trials, they can regain public trust! But this publication is not even objective enough to point this out, so probably is on Big Pharma's pay role as well!!!

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
A new report examines the safety of bivalent COVID boosters among 1.7 million over-50s